Last reviewed · How we verify
Candesartan/HCT
Candesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide acts as a diuretic to reduce fluid volume.
Candesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide acts as a diuretic to reduce fluid volume. Used for Hypertension, Reduction of cardiovascular events in patients with hypertension.
At a glance
| Generic name | Candesartan/HCT |
|---|---|
| Sponsor | Population Health Research Institute |
| Drug class | Angiotensin II receptor blocker / Thiazide diuretic combination |
| Target | AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Candesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels, causing vasodilation and reduced blood pressure. Hydrochlorothiazide (HCT) is a thiazide diuretic that increases sodium and water excretion, further reducing blood volume and blood pressure. The combination provides complementary antihypertensive effects.
Approved indications
- Hypertension
- Reduction of cardiovascular events in patients with hypertension
Common side effects
- Dizziness
- Hyperkalemia (candesartan component)
- Hypokalemia (HCT component)
- Headache
- Fatigue
- Hyperglycemia
- Hyperuricemia
Key clinical trials
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- Heart Outcomes Prevention Evaluation-3 (PHASE4)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions (PHASE3)
- Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension. (PHASE4)
- Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo (PHASE3)
- Candesartan Effect in Second Stage Arterial Hypertension (PHASE4)
- Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candesartan/HCT CI brief — competitive landscape report
- Candesartan/HCT updates RSS · CI watch RSS
- Population Health Research Institute portfolio CI